370 related articles for article (PubMed ID: 30971657)
1. [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].
Sato T; Kuba K
Nihon Yakurigaku Zasshi; 2019; 153(4):172-178. PubMed ID: 30971657
[TBL] [Abstract][Full Text] [Related]
2. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.
Kuba K; Sato T; Imai Y; Yamaguchi T
Peptides; 2019 Jan; 111():62-70. PubMed ID: 29684595
[TBL] [Abstract][Full Text] [Related]
3. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
Sato T; Sato C; Kadowaki A; Watanabe H; Ho L; Ishida J; Yamaguchi T; Kimura A; Fukamizu A; Penninger JM; Reversade B; Ito H; Imai Y; Kuba K
Cardiovasc Res; 2017 Jun; 113(7):760-769. PubMed ID: 28371822
[TBL] [Abstract][Full Text] [Related]
4. Targeting drugs to APJ receptor: From signaling to pathophysiological effects.
Huang Z; He L; Chen Z; Chen L
J Cell Physiol; 2018 Jan; 234(1):61-74. PubMed ID: 30070701
[TBL] [Abstract][Full Text] [Related]
5. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.
Yang P; Maguire JJ; Davenport AP
Trends Pharmacol Sci; 2015 Sep; 36(9):560-7. PubMed ID: 26143239
[TBL] [Abstract][Full Text] [Related]
6. The Elabela-APJ axis: a promising therapeutic target for heart failure.
Ma Z; Song JJ; Martin S; Yang XC; Zhong JC
Heart Fail Rev; 2021 Sep; 26(5):1249-1258. PubMed ID: 32314083
[TBL] [Abstract][Full Text] [Related]
7. Biological functions of Elabela, a novel endogenous ligand of APJ receptor.
Xu J; Chen L; Jiang Z; Li L
J Cell Physiol; 2018 Sep; 233(9):6472-6482. PubMed ID: 29350399
[TBL] [Abstract][Full Text] [Related]
8. Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension.
Song J; Tang J; Zhang Z; Liu Y; Zhong J
Chin Med J (Engl); 2022 May; 135(9):1019-1026. PubMed ID: 34608073
[TBL] [Abstract][Full Text] [Related]
9. A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Failure and Hypertension.
Rozwadowski J; Borodzicz-Jażdżyk S; Czarzasta K; Cudnoch-Jędrzejewska A
Med Sci Monit; 2022 Dec; 28():e938112. PubMed ID: 36523134
[TBL] [Abstract][Full Text] [Related]
10. Apelin/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential.
Pang B; Jiang YR; Xu JY; Shao DX; Hao LY
Eur J Pharmacol; 2023 Jun; 949():175727. PubMed ID: 37062502
[TBL] [Abstract][Full Text] [Related]
11. Apelin receptors: From signaling to antidiabetic strategy.
Chaves-Almagro C; Castan-Laurell I; Dray C; Knauf C; Valet P; Masri B
Eur J Pharmacol; 2015 Sep; 763(Pt B):149-59. PubMed ID: 26007641
[TBL] [Abstract][Full Text] [Related]
12. Elabela/Toddler and apelin bind differently to the apelin receptor.
Couvineau P; Llorens-Cortes C; Iturrioz X
FASEB J; 2020 Jun; 34(6):7989-8000. PubMed ID: 32301550
[TBL] [Abstract][Full Text] [Related]
13. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR.
Chapman NA; Dupré DJ; Rainey JK
Biochem Cell Biol; 2014 Dec; 92(6):431-40. PubMed ID: 25275559
[TBL] [Abstract][Full Text] [Related]
14. Apelin and its receptor APJ in cardiovascular diseases.
Yu XH; Tang ZB; Liu LJ; Qian H; Tang SL; Zhang DW; Tian GP; Tang CK
Clin Chim Acta; 2014 Jan; 428():1-8. PubMed ID: 24055369
[TBL] [Abstract][Full Text] [Related]
15. Apelin is a positive regulator of ACE2 in failing hearts.
Sato T; Suzuki T; Watanabe H; Kadowaki A; Fukamizu A; Liu PP; Kimura A; Ito H; Penninger JM; Imai Y; Kuba K
J Clin Invest; 2013 Dec; 123(12):5203-11. PubMed ID: 24177423
[TBL] [Abstract][Full Text] [Related]
16. Translational promise of the apelin--APJ system.
Barnes G; Japp AG; Newby DE
Heart; 2010 Jul; 96(13):1011-6. PubMed ID: 20584856
[TBL] [Abstract][Full Text] [Related]
17. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease.
Charles CJ
Cardiovasc Hematol Agents Med Chem; 2007 Jan; 5(1):1-10. PubMed ID: 17266543
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target.
Xu C
Vascul Pharmacol; 2023 Aug; 151():107193. PubMed ID: 37433415
[TBL] [Abstract][Full Text] [Related]
19. Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling.
Deng C; Chen H; Yang N; Feng Y; Hsueh AJ
J Biol Chem; 2015 Jul; 290(30):18261-8. PubMed ID: 25995451
[TBL] [Abstract][Full Text] [Related]
20. Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system.
Liu W; Yan J; Pan W; Tang M
Ann Transl Med; 2020 Mar; 8(5):243. PubMed ID: 32309390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
